Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-EGFR-IL-dox
- Development stage
- Discontinued
- Lead developer
- Swiss Group for Clinical Cancer Research
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
anti-EGFR-IL-dox is a targeted biologic nanoparticle drug delivery system (immunoliposome) developed for the treatment of EGFR-positive cancers. It consists of pegylated liposomes loaded with the cytotoxic payload doxorubicin, with anti-EGFR antibody fragments (specifically cetuximab fragments) inserted into the liposomal membrane to facilitate targeted delivery. By targeting the epidermal growth factor receptor (EGFR), which is frequently overexpressed in triple-negative breast cancer (TNBC), the drug aims to increase the concentration of doxorubicin within tumor cells while reducing systemic toxicity. The drug was evaluated in a multicenter Phase II trial (NCT02833766) led by the Swiss Group for Clinical Cancer Research (SAKK) as a first-line therapy for advanced EGFR-positive TNBC. However, due to negative efficacy results, the trial concluded that the drug should not be further developed for this indication.
- Other names
- anti-EGFR immunoliposomes loaded with doxorubicindoxorubicin-loaded anti-EGFR immunoliposomesanti-EGFR-IL-doxorubicin
02
Targets
Beyond the preview
Go deeper on anti-EGFR-IL-dox.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-EGFR-IL-dox.